US equities
|
MU
$891.37
▼-4.28%
TSLA
$352.56
▼-2.73%
NVDA
$214.77
▼-1.13%
AAPL
$342.32
▲+0.10%
SPCX
$144.78
▼-2.59%
META
$706.66
▼-4.08%
SNDK
$1,324.70
▼-5.03%
MSFT
$526.04
▼-2.48%
MU
$891.37
▼-4.28%
TSLA
$352.56
▼-2.73%
NVDA
$214.77
▼-1.13%
AAPL
$342.32
▲+0.10%
SPCX
$144.78
▼-2.59%
META
$706.66
▼-4.08%
SNDK
$1,324.70
▼-5.03%
MSFT
$526.04
▼-2.48%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Dermata Therapeutics
Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment
October 15, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment
August 25, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Tickers
DRMA
DRMAW
Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch
August 21, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
August 17, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Tickers
DRMA
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
August 11, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
August 05, 2026
From
Dermata Therapeutics
Via
ACCESS Newswire
Tickers
DRMA
Dermata Announces Final Patient Enrolled in a Phase 2 Trial of DMT310 for the Once-Weekly Treatment of Moderate-to-Severe Rosacea
June 13, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata to Present at the H.C. Wainwright Global Investment Conference
May 23, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 16, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces Closing of $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 25, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
April 21, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results
March 28, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference
March 24, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors
January 13, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata to Present at the H.C. Wainwright BioConnect Conference
January 05, 2022
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
November 19, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
November 17, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Tickers
DRMA
DRMAW
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
November 12, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
November 11, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
October 18, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 27, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Tickers
DRMA
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
September 21, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer
September 01, 2021
From
Dermata Therapeutics
Via
AccessWire
Tickers
DRMA
DRMAW
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering
August 17, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Regulatory Compliance
Tickers
DRMA
DRMAW
Dermata Therapeutics, Inc. Announces Pricing of Upsized $18.0 Million Initial Public Offering
August 12, 2021
From
Dermata Therapeutics
Via
AccessWire
Topics
Regulatory Compliance
Tickers
DRMA
DRMAW
